

November 9, 2020

ONO and Bristol Myers Squibb Enter Patent License Agreement with Roche

Ono Pharmaceutical Co., Ltd. (Osaka, Japan; President, Representative Director and CEO, Gyo Sagara; “ONO”) announces that ONO and Bristol Myers Squibb Company (NYSE: BMY, “BMS”) have signed a global patent license agreement with Roche Group relating to atezolizumab (Tecentriq®), Roche’s anti-PD-L1 antibody.

Under the agreement, Roche will make an upfront payment, and will pay single-digit royalties on worldwide sales of atezolizumab from January 1, 2020 through December 31, 2026. The upfront payment and royalties will be shared between ONO and BMS consistent with existing agreements.

The impact on the consolidated financial results ending March 2021 will be disclosed at the announcement of financial result during the 3rd quarter for Fiscal Year ended March 2021.

Ono Pharmaceutical Co., Ltd.

Corporate Communications

public_relations@ono.co.jp